SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

[News]

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

More... (http://www.news-medical.net/news/20110330/SLN-to-present-Atu027-Phase-I-study-data-against-solid-cancer-at-ASCO-Annual-Meeting.aspx)